PPG Partner Yvonne Shyntum has been selected as a member of the National Science Foundation Center for Cell Manufacturing Technology (CMaT)’s Commercialization Advisory Board.
Led by the Georgia Institute of Technology, CMaT is a multi-institutional center focused on the creation of new tools and technologies to make therapeutic cell manufacturing more reproducible, scalable, cost effective and widely available to the people that need them. The technologies being developed in CMaT include innovations such as: in-line process analytical control technologies; non-viral chimeric antigen receptor (CAR) T cell technologies; processes for developing iPSC cardiomyocytes, potency assays, novel biomaterials for bioreactors; and new supply chain modeling algorithms for the cell manufacturing industry.
The Center is comprised of 7 universities (Georgia Tech, University of Georgia, University of Wisconsin, University of Mayagüez in Puerto Rico, University of Pennsylvania Health System, University of Oregon, and Emory University). The Center also relies on a strong industry consortium of over 20 companies to provide guidance and direction for research. International partners include the Centre for Commercialization of Regenerative Medicine in Toronto, CÚRAM in Ireland, and Osaka University.
Dr. Shyntum brings a sophisticated understanding of complex science and technology subjects to her work, aided by her Ph.D. in pharmacology as well as training in molecular biology, animal models of human disease, redox biology and toxicology. She combines a passion for discovery with savvy for finding the most innovative, practical, and efficient legal solutions for her clients.
In her new role as a member of the Commercialization Advisory Board, Dr. Shyntum will have the opportunity to preview promising new cell and gene therapy tools and technologies created by the Center. As a board member, she will also provide her expertise and advice on the commercialization readiness of the technologies, and identify gaps and hurdles that need to be addressed to further translate the technologies from bench to market.
